Skip to main content
S&P 5007,608.83+0.30%DOW52,075.44-0.03%NASDAQ26,150.11+0.65%BTC$75,716.00-0.66%ETH$2,390.66-1.01%GOLD$4,385.10+1.21%OIL$102.52-3.13%
Smart Investors Daily
TR

NASDAQ · TRVI

Trevi Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$15.04

Up+$0.19 (+1.25%)

Updated Sep 16, 2026, 5:22 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.69B
P/E ratio
-41.7
Dividend yield
0.00%
52-week range
$10.25 – $20.22
Volume
2.57M
Avg. volume
1.99M

Price performance

TRVI price history

1M range · 20 trading sessions · Daily adjusted prices

TRVI closed at $15.04 after 20 trading sessions, down 20.17% for the selected period.

Last close
$15.04
Period change
-20.17%
Period low
$15.04
Period high
$18.84
Daily close
View OHLC price history
TRVI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$15.88$15.88$14.78$15.042.57M
Sep 14, 2026$16.00$16.1694$15.82$15.891.06M
Sep 11, 2026$16.20$16.57$15.87$15.902.02M
Sep 10, 2026$16.51$16.51$15.71$15.911.25M
Sep 9, 2026$16.87$17.025$16.51$16.64959.54K
Sep 8, 2026$16.94$17.18$16.59$16.821.49M
Sep 4, 2026$16.88$17.315$16.80$17.26856.67K
Sep 3, 2026$17.09$17.15$16.47$17.061.43M
Sep 2, 2026$16.57$17.115$16.22$17.051.35M
Sep 1, 2026$16.40$16.73$16.32$16.57945.06K
Aug 31, 2026$16.66$16.735$16.0803$16.601.87M
Aug 28, 2026$17.88$18.0899$16.625$16.791.97M
Aug 27, 2026$17.85$18.105$17.61$17.961.23M
Aug 26, 2026$17.89$18.005$17.42$17.921.21M
Aug 25, 2026$18.29$18.59$17.69$17.952.14M
Aug 24, 2026$17.855$18.125$17.24$18.081.23M
Aug 21, 2026$18.44$18.54$17.83$17.961.14M
Aug 20, 2026$18.59$18.99$18.15$18.251.25M
Aug 19, 2026$19.29$19.30$18.50$18.811.98M
Aug 18, 2026$18.46$18.97$18.18$18.841.75M

Latest TRVI news

The latest Smart Investors Daily articles mentioning TRVI.

Stock researchCompany · Overview

TRVI research

Overview

Company profile and research snapshot.

Company profile

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$19.67
Implied upside
—
Analysts
—
TRVI recent ratings
DateFirmRatingTarget
Aug 14, 2026Jones TradingBuy—
Aug 7, 2026OppenheimerOutperform—
Aug 7, 2026Cantor FitzgeraldOverweight—
Jul 21, 2026BMO CapitalOutperform—
Jul 20, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 17, 2026

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Fireside chat with management on February 25, 2026, at 9:20 a.m. ETNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chie

Yahoo · Jan 14, 2026

BioCT Appoints Four Distinguished Life Sciences Leaders to Board of Directors

NEW HAVEN, Conn., January 14, 2026--BioCT, Connecticut’s life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Jennifer Good, Co-Founder, President, and Chief Execu

Yahoo · Jan 11, 2026

Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism

Trevi Therapeutics (TRVI) recently drew fresh attention after updating investors on its clinical plans, including an upcoming FDA End of Phase 2 meeting for its chronic cough program in idiopathic pulmonary fibrosis. See our latest analysis for Trevi Therapeutics. Those clinical updates and recent broker commentary come after a mixed price patch, with the share price at US$11.18, a 30 day share price return of a 12.45% decline, a 90 day share price return of a 15.14% gain, and a 1 year total...

Yahoo · Jan 11, 2026

Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy?

Trevi Therapeutics recently outlined past and upcoming milestones for its chronic cough portfolio, including an FDA End-of-Phase 2 meeting in early 2026 and planned Phase 3 and Phase 2b trial initiations for nalbuphine ER in idiopathic pulmonary fibrosis and refractory chronic cough patients, respectively. This progress highlights Trevi’s effort to position nalbuphine ER across multiple chronic cough indications, potentially broadening its future addressable treatment landscape. We’ll now...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By